Vertex Pharmaceuticals Incorporated Class Action Lawsuit - VRTX

The filed complaint alleges that Vertex Pharmaceuticals Incorporated made materially false and/or misleading statements and/or failed to disclose that: On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine. The trial, which targeted pain caused by a pinched nerve in the spine, showed no significant difference in pain reduction compared to a placebo. The company also announced plans to proceed with a Phase 3 trial for suzetrigine, a decision that has left some analysts questioning the rationale. One commentator stated on X "Vertex often gets the benefit of the doubt given its track record, but damn, this one is tough to reconcile." The company's announcements come mere days after insider transactions have been reported. Following this news, shares of Vertex fell 12% in morning trading on the same day.

In order to be eligible to join the VRTX class action lawsuit, you must have incurred a loss on shares of Vertex Pharmaceuticals purchased during the class period listed above.